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VACCINE HESITANCY:  




 Vaccines are one of the greatest public health interventions in modern 
times. Their development has drastically reduced the global burden of infectious 
disease. However, rising vaccine hesitancy is contributing to the reemergence of 
vaccine-preventable diseases. The reasons for vaccine hesitancy are complex 
and diverse. This paper aims to explore the reasons why vaccine hesitancy 
persists. These reasons include safety concerns, spread of misinformation, 
religion and culture, awareness and knowledge, personal and philosophical 
beliefs, and the patient-provider relationship. There is no single solution to 
addressing vaccine hesitancy. Providers play an important role in influencing an 
individual’s decisions about vaccination. Motivational interviewing and other 
communication strategies are helpful in establishing trust with hesitant 
individuals. Monitoring online information can elucidate trends of public sentiment 
about vaccines and prepare health officials for spikes in vaccine hesitancy. 
Policy-based interventions may cause more harm than good. Community-based 
solutions are particularly effective in regions where resources are scarce. 
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Vaccines are one of the greatest public health achievements in modern 
times. The Centers for Disease Control and Prevention (CDC) estimates 
vaccination will avert over 21 million hospitalizations, 732,000 pre-mature deaths, 
and $401 billion in direct costs from vaccine-preventable diseases (VPDs) over 
the life courses of children born in the United States during 1994-2013.1 The 
World Health Organization (WHO) reports vaccines have prevented at least 10 
million deaths worldwide between 2010 – 2015.2 In many countries, routine 
vaccination efforts have led to the mitigation and, in some cases, the elimination 
of several infectious diseases.3,4 In 1980, the world eradicated its first VPD – 
smallpox.5 However, rising vaccine hesitancy (VH) is causing the reemergence of 
VPDs in both developed and developing countries. VH is a complex issue with no 
single solution, yet its danger to public health is very real; the WHO listed VH as 
one the ten threats to global health in 2019.6  
This thesis will explore and compare the various factors that contribute to 
VH around the world. Next, strategies that are being used to address VH will be 
discussed by evaluating current literature. In the following introduction, additional 
background on vaccination and the history of vaccines will be detailed, and 




Vaccine History and Smallpox 
While modern vaccinology is a relatively young discipline, the concept of 
immunization dates back many centuries. Shortly before the start of the Common 
Era, King Mithridates VI is believed to have ingested daily, sub-lethal doses of 
poison in order to prevent poison-related assassination attempts.7 During the 
seventh century in India, Buddhists supposedly drank snake venom to protect 
against fatal snake bites.8 Later in China during the seventeenth century, 
members of royalty were inoculated against smallpox by wearing clothing 
contaminated with smallpox pustules.9 However, these methods produced 
unstable results. It would take another century until vaccination was reliably 
effective and backed by empirical evidence.  
 Throughout the course of human history, the variola virus, or smallpox, 
has been responsible for the decline of empires and decimation of 
populations.5,10 It is estimated that across Europe in the late eighteenth century, 
smallpox was annually responsible for 400,000 deaths and the permanent 
disfigurement of countless others.11 This would change, however, when in 1796 
an English physician named Edward Jenner made a revolutionary discovery. He 
noticed milkmaids who developed cowpox pustules were immune from 
contracting smallpox. To test these observations, Jenner conducted an 
experiment where he deliberately scraped material from a cowpox pustule into 
the skin of a young boy. Although the boy went on to develop cowpox-like 
pustules, he was spared fever, chills, and other symptoms associated with 
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cowpox disease. Six weeks later, Jenner showed the world that the boy was also 
immune to smallpox.12 Jenner continued experimenting with his cowpox vaccine 
and in 1798 he published Inquiry into the Causes and Effects of the Variolae 
Vaccinae. Although the publication had several flaws13 (Jenner inaccurately 
claimed a single cowpox variolation conferred lifelong immunity against 
smallpox), its contents laid the foundation for modern vaccinology.  
 In the following century, scientific knowledge of vaccines would 
exponentially grow from the works of Louis Pasteur and other scientists. By the 
1900s, there were two human virus vaccines for smallpox and rabies, and three 
bacterial vaccines against cholera, typhoid, and the plague.14 The rise of new 
vaccines and understanding of infectious disease prompted world leaders and 
the scientific community to push for the elimination, and even eradication, of 
VPDs. The impact of vaccines on disease burden in the United States is 
highlighted in Table 1 and Table 2. 
 Vaccines are a biologic preparation that help develop immunity to a 
specific pathogen or specific set of one or more antigens.15 Vaccines protect 
humans against bacterial and viral infections by introducing antigen (foreign 
substance) to the host’s immune system, resulting in the activation of B-
lymphocytes, cells that produce antibodies, and other immune-specific cells, like 
T-lymphocytes. Antibodies are large proteins that recognize and bind to unique 
molecular regions on antigens. Some antibodies have neutralizing properties 
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when bound to antigens, effectively preventing the pathogen from causing 
cellular damage. Other antibodies signal for attack by immune cells.15  
 
 
Table 1. Vaccine-related decrease in morbidity, 20th century vs 201715 
 
Disease 20
th Century Annual 
Morbidity 
2017 Reported 
Cases % Decrease 
Smallpox  29,005 0 100% 
Diphtheria  21,053 0 100% 
Pertussis 200,752 15,808 92% 
Tetanus  580 31 95% 
Polio (paralytic) 16,316 0 100% 
Measles 530,217 122 >99% 
Mumps  162,334 5629 97% 
Rubella  47,745 9 >99% 
CRS (congenital 
rubella syndrome) 152 2 99% 
Haemophilus 
influenzae 20,000 (est.) 22 >99% 
 
 
Table 2. Vaccine-related decrease in morbidity, pre-vaccine era vs 201515 
 





Hepatitis A 117,333 2,500* 98% 
Hepatitis B (acute) 66,232 19,200* 71% 
Pneumococcus (invasive) 
     All ages 








(hospitalizations <3 years of 
age) 
62,500 11,250 82% 
Varicella  4,085,120 126,639 97% 




Humans can acquire immunity passively or actively. Passive immunity 
occurs when antibodies produced from one animal or human are transferred to 
another.15 Passive immunity provides immediate protection against infection; 
however, this protection is short lived as antibodies are typically cleared from the 
body within weeks to months.15 Infants acquire passive immunity through IgG 
antibodies produced by the mother and transported across the placenta during 
the last 1-2 months of pregnancy. As a result, babies are protected from certain 
diseases within the first few months after birth.15 Passive immunity can also 
occur through transfusion of antibodies found in blood products.15 These 
transfusions are used for postexposure prophylaxis against diseases like rabies 
and tetanus. Lastly, therapeutic monoclonal antibodies are used as treatments 
for cancer, autoimmune diseases, and infectious diseases.15 
 Active immunity occurs when exposure to an antigen causes an 
individual’s own immune system to produce antibodies and cell mediated 
immunity. In contrast to passive immunity, active immunity is longer lived, often 
lasting a lifetime.15 Active immunity is acquired from catching and recovering 
from most infectious diseases. Vaccination is another way of acquiring active 
immunity. The active immunity achieved through vaccination is not only 
comparable to natural infection but is also safer as the vaccine recipient does not 
contract the disease.15 There are several types of vaccines used to produce 
active immunity. Live, attenuated vaccines contain a weakened form of the 
pathogen and replicate in the recipient’s body. Inactivated vaccines contain killed 
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pathogens and, therefore, cannot replicate. Toxoid vaccines contain inactivated 
toxins. Subunit, polysaccharide and conjugate vaccines contain a specific piece 
of the pathogen, such as the pathogen’s protein or saccharide molecules. 
Recombinant vaccines contain live viral or bacterial vector that express surface 
antigens engineered through recombinant DNA technology. Live vaccines 
generally produce a stronger immune response and require less doses than 
inactivated vaccines.15 
 Herd immunity is a form of indirect protection from disease that occurs 
when a large percentage of a population is unable to transmit a pathogen due to 
some form of immune response, usually through vaccination.3 This protection is 
particularly important for population members who cannot be vaccinated due to 
medical contraindications. Herd immunity also stops the transmission of disease 
and is a critical step needed for elimination and eradication of VPDs.3  
 
Polio, IPV, and OPV 
 Polio, short for poliomyelitis, is an infectious disease caused by the 
poliovirus.16 The majority of people infected with the poliovirus are asymptomatic; 
however, some will develop life-threatening symptoms such as paralysis and 
aseptic meningitis. Others will suffer from post-polio syndrome: the development 
of muscle weakness, pain, or paralysis 15-40 years after recovery from initial 
infection.16 The death-to-case ratio for paralytic polio is estimated 2%-5% among 
children, and 15%-30% in adults.15  In 1952, the need for a polio vaccine in the 
	
7 
United States was evident; paralytic polio had reached a peak of 21,000 cases 
that year.15 A few years later, an American physician named Jonas Salk would 
discover that formaldehyde inactivated the poliovirus, but kept the virus’s 
antigenic properties.17 Salk realized inactivated poliovirus was capable of 
triggering an immune response without the risk of causing infection, making it an 
ideal substance for a vaccine. The novel inactivated poliovirus vaccine (IPV) was 
subjected to a large-scale multi-nation study with over one million pediatric 
subjects.18 In 1955, Salk and his team announced the vaccine’s success, 
prompting mass-production and distribution of the IPV nationwide. Salk’s IPV 
was administered via intramuscular injection and contained three different strains 
of virus: Mahoney (type-1), MEF-I (type-2), and Saukett (type-3). After adoption 
of the Salk vaccine, the incidence of paralytic polio in the United States dropped 
from 13.9 cases per 100,000 in 1954 to 0.8 cases per 100,000 in 1961.19 By 
1959, Salk’s vaccine had reached over 90 countries.17 
The Salk vaccine, however, had several limitations and setbacks during 
this time. Titers of circulating protective antibodies sharply decreased within a 
few years of initial vaccination.19 Furthermore, large numbers of monkeys 
(around 1500) needed to be sacrificed for every one million IPV doses 
produced.19 The Salk vaccine received its sharpest criticism shortly after its 
licensure when a manufacturing failure at the Cutter Laboratories, Berkeley led to 
a contamination of live type-1 polio virus in more than 100,000 doses, causing 
260 cases of paralytic poliomyelitis and 10 deaths.19 This incident weakened 
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public trust in the IPV and resulted in decreased polio vaccination coverage 
throughout the United States. 
 Around this time, Albert Sabin was developing a different polio vaccine. 
The Sabin oral polio vaccine (OPV) consisted of three live attenuated poliovirus 
strains. Because Sabin’s vaccine produced good antibody titers, and in part due 
to the Cutter incident, the OPV was approved and largely replaced IPV in the 
United States and other countries in 1961.19 The OPV, however, also had its 
share of complications. While the incidence of worldwide poliomyelitis markedly 
declined from multi-nation OPV campaign initiatives between 1961-1978, 
vaccine-associated paralytic poliomyelitis (VAPP) cases began to appear.19 In 
response to rising concerns about VAPP, an enhanced-potency IPV was 
developed and made available in 1988. As IPV poses no risk of vaccine-
associated paralytic disease, many countries have switched their vaccine 
schedules to include IPV instead of OPV.19 The use of OPV was discontinued in 
the United States in 2000.15  
 The United States saw its last case of indigenously transmitted wild 
poliovirus in 1979.15 Following a concerted effort by the member countries of the 
Pan American Health Organization, the Western Hemisphere was certified polio 
free in 1994.15 In 1988, the World Health Assembly (WHA) set the goal of global 
eradication of polio by the year 2000. Shortly after the WHA’s announcement, the 
Global Polio Eradication Initiative (GPEI) was created. While the goal of global 
eradication was not reached, much progress has been made. The estimated 
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global number of paralytic polio cases has dramatically decreased from 350,000 
in 1988 to 223 in 2012.15 In 2019, the GEPI reported a total of 176 cases of wild 
polio, globally.20 Although significant progress has been made towards global 
eradication, poliovirus remains endemic in three countries.15 Hesitancy towards 
the polio vaccine remains a major barrier to interrupting transmission and 
achieving global eradication.21,22   
 
Measles and the MMR Vaccine 
 Measles is an infectious disease caused by the measles virus, a member 
of the paramyxovirus family. The disease is characterized by high fever followed 
by cough, coryza and/or conjunctivitis, and a red, flat rash which starts on the 
face and then spreads to the rest of the body.15 While the majority of individuals 
infected with measles make a full recovery, approximately 30% of reported cases 
have one or more measles-related complications, with complications being most 
common among children younger than 5 years of age and adults 20 years of age 
and older.15 Based on 1985 to 1992 CDC surveillance data, diarrhea was the 
most prevalent complication occurring in 8% of reported cases.15 Otitis media 
(7%), pneumonia (6%), seizures (0.6-0.7%), encephalitis (0.1%), and death 
(0.2%) were other complications reported among measles cases from the 
surveillance data.  
 Like smallpox and polio, measles has burdened humans throughout 
history. The earliest recorded outbreaks of measles occurred in China and the 
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Roman Empire during the second and fourth centuries, respectively.23 Measles 
virus is primarily transmitted via respiratory droplets, and is highly contagious 
with an estimated basic reproductive number – the number of expected 
secondary cases generated per primary case (also denoted as R0) – greater than 
12.24 In contrast, the R0 of mumps virus, also a paramyxovirus, is 5. In the pre-
vaccine era, roughly 500,000 cases and 500 measles-related deaths were 
reported annually in the United States.15 Globally, an estimated 135 million cases 
and 6 million-measles related deaths occurred each year.25 According to the 
CDC, 5 to 9 year-olds made the highest incidence of measles cases in the United 
States during this time, accounting for more than 50% of total reported cases.15  
 In 1954, John F. Enders and Dr. Thomas C. Peebles achieved a milestone 
by successfully isolating measles from the blood of a young boy named David 
Edmonston.24  In 1963, Enders and his colleagues used the Edmonston-B strain 
to develop and license the first live, attenuated vaccine for measles. Another 
vaccine, using the Edmonston-Enders strain to strengthen immunogenicity, was 
developed by Maurice Hilleman in 1968.24 In 1971, Hilleman created the trivalent 
Measles-Mumps-Rubella (MMR) vaccine by combining his measles strain with 
live, attenuated strains of the mumps and rubella viruses. Following its approval 
in the United States, the MMR vaccine replaced monovalent measles, mumps 
(approved in 1967) and rubella (approved in 1969) vaccines. The MMR vaccine 
was originally approved for single dose use in children 9 months of age; 
however, in 1989, the CDC recommended children receive two doses to confer 
	
11 
longer immunity.26 The CDC currently recommends eligible children receive their 
first dose at 12 to 15 months of age, followed by the second dose at 4 to 6 years 
of age.  
 The development of the measles vaccine led to a 60% reduction in cases 
in the United States by 1966 (Figure 1).26 In 1967, the United States devised a 
plan for measles elimination that centered around four strategies: 1) routine 
vaccination of infants, 2) immunization of all susceptible children at school entry, 
3) surveillance, and 4) epidemic control.27 These strategies, combined with the 
1971 MMR vaccine, resulted in a 96% decrease in reported cases of measles, 
mumps, and rubella in the United States by 1988.28 An estimated 74.5 million 
cases of measles and 7,450 deaths have been averted since the discovery of the 
measles vaccine in 1963. The MMR vaccine had helped save the United States 
$1.3 billion in healthcare related costs by 1983.28 In England, vaccination 
coverage for measles reached 86% after the introduction of the MMR vaccine in 









Figure 1. Reported measles cases by year in the United States, 1962-2014.26 
 
 During the 1980s in the United States, measles occurred primarily among 
unvaccinated preschool-aged and school-aged children. A measles resurgence, 
causing 53,685 reported cases and 123 measles-related deaths, occurred 
among unvaccinated preschool aged children living in low-income, urban areas 
during 1989-1991.26 This outbreak highlighted the importance of on-time 
vaccination schedules among preschool populations. The resurgence also 
revealed the disparity of VPD burden and poor access to vaccination services in 
low-income communities. These revelations prompted the creation of the 
Vaccines for Children Program in 1993, a federally funded initiative that provides 
vaccines at no cost for needy children.26 First dose-measles coverage among 
children 19 to 35 months of age had reached 90% by the mid 1990s, 
corresponding to a sustained incidence of less than 1 case of measles per million 
1971 
MMR Vaccine Licensed 
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throughout the 1990s.26 By 2000, measles was declared no longer endemic in 
the United States.  
 Global measles control has also been very successful. The estimated 
worldwide one-year measles mortality fell from 535,300 deaths in 2000 to 
139,300 deaths in 2010, corresponding to a 74% reduction.30 From 2000 to 2018, 
the WHO estimates measles vaccination has averted 23.2 million deaths and 
saved trillions of dollars in societal costs, making measles vaccination one of the 
most cost-effective public health interventions.2  
 Yet, measles remains a threat in parts of the world and, as of recently, is 
making a resurgence. In 2017, the global coverage for first and second dose 
measles vaccines was 85% and 67%, respectively – well below the WHO’s 
recommendation of 95% coverage needed for worldwide eradication.31 The WHO 
announced that during 2019 there were more cases reported globally than any 
year since 2006, with more than 500,000 confirmed cases among 180 countries 
(Figure 2).32 This outbreak caused four European countries (Albania, Czechia, 
Greece and the United Kingdom) to lose their measles elimination statuses, and 
put the United States, who reported its highest number of cases (>1200) in over 
two decades, in jeopardy of losing its status. Following the outbreak, several key 
social and physical determinants responsible for driving high case numbers and 
low vaccine uptake were identified: war and political conflict; socioeconomic 
collapse related to climate change, food insecurity, and urbanization; poor 




Figure 2. Measles case distribution by month and WHO region (2015 – 8 November 2019).32 
AFR = African Region, AMR = Region for the Americas, EMR = Eastern Mediterranean Region, 
EUR = European Region, SEAR = South-East Asia Region, WPR = Western Pacific Region. 
 
Vaccine Hesitancy and the SAGE Working Group  
Resistance to vaccination has occurred since Jenner’s introduction of the 
smallpox vaccine in 1796.34,35 Throughout the world during the 1800s, anti-
vaccination groups started forming to oppose compulsory vaccination laws.36 
People were concerned for a variety of reasons; some questioned the safety of 
vaccines, while others feared the science and thought vaccinology went against 
Divine will.13,34 In the United States during the early 1900s, opposition to 
mandatory smallpox vaccination law resulted in the 1905 Supreme Court Case 




mandatory vaccination is legal when in the interest of protecting the public’s 
health.37 
While hesitancy of vaccines is not a new phenomenon, it has been 
steadily on the rise in recent decades. The Strategic Advisory Group of Experts 
(SAGE) on Immunization was established in 1999 and is the primary advisory 
group to the WHO for vaccines and immunizations. In 2012, the SAGE Working 
Group on Vaccine Hesitancy (WG) was convened to address the growing 
negative impact hesitancy was having on worldwide vaccination coverage rates. 
The WG’s main objectives were to define VH, understand its scope, and 
categorize the factors that influence the behavioral decision to delay 
vaccination.38  
 In respect to the scope of VH, the WG determined VH lies on a continuum 
between the vast majority that accept vaccines without reservations, and the 
small minority that outright refuse all vaccines (Figure 3).38 This VH continuum 
has two important implications: 1) vaccine hesitant individuals are a 
heterogenous group containing a diverse range of opinions and beliefs about 
vaccines and vaccination, with more individuals closer to the “Accept All” extreme 
than the “Refuse But Unsure” and “Refuse All” extremes, and 2) only a small 
fraction of a given population absolutely refuse vaccines. The WG further 
emphasized that VH is a behavioral phenomenon and may explain low 
vaccination coverage, provided other explanations have been considered.38 For 
example, VH may not fully explain low uptake in a population where other 
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systemic and natural barriers exist (poor access to immunization services due to 
limited resources, natural disasters and/or conflict, low supply of vaccines, etc.). 
Lastly, the WG argues vaccine demand should be taken into account. Although 
Figure 3 suggests that the VH continuum also lies between “High Demand” and 
“No Demand” of vaccines, this is not always accurate. Some communities may 
fully accept vaccines and experience no hesitancy, but the demand for 
vaccination or a specific vaccine is in fact low.38 
 
 
Figure 3. The continuum of vaccine hesitancy between full acceptance and full refusal of 
all vaccines.38  
 
In developing their definition of VH, the WG in 2012 agreed on the “Three 
Cs” (Confidence, Complacency, and Convenience) conceptual model for 
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grouping VH determinants together. This model was chosen for its clarity as 
individuals who are unfamiliar with the term VH can still easily understand the 
components of the “Three Cs.”   In the “Three Cs” model, confidence refers to 
trust in the efficacy and safety of vaccines, the healthcare system that delivers 
them, and the motivations of lawmakers and their policy on vaccines. 
Complacency occurs when perceived risks of VPD are lower than perceived 
benefits of vaccination at that time. Many life/health factors may influence 
vaccination complacency. Paradoxically, successful vaccination campaigns may 
lead to complacency, and ultimately hesitancy, as increased vaccination 
coverage results in decreased prevalence of VPDs, which in turn results in 
reduced perceived risk of a specific VPD or VPDs in general. For example, 
complacency of the MMR vaccine is thought to have partially caused a 
resurgence of measles cases in the United States during the 2010s.39 Finally, 
vaccination convenience encompasses factors like physical availability, 
affordability and willingness-to-pay, geographical accessibility, language and 
health literacy, cultural sensitivity, and appeal of vaccination services that affect 
coverage.38 
After choosing to include the “Three Cs” model into the definition of VH, 
the WG developed the Vaccine Hesitancy Determinants Matrix with factors 
grouped into three categories: 1) contextual, 2) individual and group, and 3) 
vaccine/vaccination-specific influences (Table 3).38 The matrix includes 
18 
determinants identified from research studies, experiences of WG members in 
the field, and conversations with experts.38 
Table 3. Determinants of Vaccine Hesitancy Grouped by Category.38 See Appendix 1 for a 
more detailed matrix.  
CONTEXTUAL INFLUENCES 
Influences arising due to historic, 
socio-cultural, environmental, 
health system/institutional, 
economic or political factors 
a. Communication and media environment
b. Influential leaders, immunization program gatekeepers





g. Perception of the pharmaceutical industry
INDIVIDUAL AND GROUP 
INFLUENCES  
Influences arising from personal 
perception of the vaccine or 
influences of the social/peer 
environment  
a. Personal, family and/or community members’
experience with vaccination, including pain
b. Beliefs, attitudes about health and prevention
c. Knowledge/awareness
d. Health system and providers-trust and personal
experience
e. Risk/benefit (perceived, heuristic) Immunization as a
social norm vs. not needed/harmful
VACCINE/ VACCINATION– 
SPECIFIC ISSUES  
Directly related to vaccine or 
vaccination  
a. Risk/ Benefit (epidemiological and scientific evidence)
b. Introduction of a new vaccine or new formulation or a
new recommendation for an existing vaccine
c. Mode of administration
d. Design of vaccination program/Mode of delivery (e.g.,
routine program or mass vaccination campaign)




h. The strength of the recommendation and/or




The WG concluded its deliberations and settled on the following definition of VH:  
Vaccine hesitancy refers to delay in acceptance or refusal of 
vaccination despite availability of vaccination services. Vaccine 
hesitancy is complex and context specific, varying across time, 
place and vaccines. It is influenced by factors such as 
complacency, convenience and confidence.38 
 
Vaccine hesitant individuals may accept some vaccines, delay recommended 
vaccination schedules, or outright refuse all vaccination services. Vaccine 
hesitant parents (VHPs) who choose to not vaccinate put their child at higher risk 
of contracting a VPD.40 In addition, VH is causing cases of previously well-
controlled VPDs to reemerge in countries around the world.41 VH also reduces 
herd immunity and weakens protection for those ineligible for vaccination. The 




REASONS FOR VACCINE HESITANCY 
 
Safety Concerns and Technology 
 Safety concerns about vaccines are one of the greatest drivers of VH. 
Many VHPs express worry about the potential short- and long-term 
consequences of vaccinating their children.42–45  One study found parents with 
unvaccinated children (non-medical exemptions) had lower perceived safety of 
vaccines compared to parents with fully vaccinated children (61% vs. 15%).46 In 
the same study, parents with low perceived safety were most concerned that 
vaccines cause harm to their child (69%), followed by concerns that vaccines 
overstimulate their child’s immune system (49%).  
Individuals with vaccine safety concerns believe the chemical ingredients 
of vaccines, namely thimerosal and aluminum, are toxic. Thimerosal, a mercury-
containing organic compound, has been frequently used as an antimicrobial 
preservative in multi-dose vaccine vials since the 1930s.47 Yet, unlike the well-
documented neurotoxic effects of methylmercury found in fish, the toxic effects of 
thimerosal (ethylmercury) remain controversial. Associated effects range from 
mild, local reactions at the site of injection only,48–50 to more adverse 
developmental and behavioral outcomes such as tic disorder.51,52 However, there 
is no evidence supporting a causal pathway between thimerosal containing 
vaccines and adverse developmental disorders in children. The United States 
Food and Drug Administration (FDA) tightly regulates thimerosal in vaccines. 
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Today, there are thimerosal-free preparations for all vaccines routinely given to 
children 6 years of age and younger in the United States.47 However, 
manufacturing alternatives to thimerosal is costly. As a result, many developing 
countries still use multi-dose vials containing thimerosal.51 
Aluminum is another ingredient frequently questioned for its safety. 
Aluminum salts are used in vaccines as an adjuvant, a chemical that stimulates 
the body’s immune response to antigen.53 Many licensed vaccines in the United 
States, including DTaP (diphtheria, tetanus, and pertussis), pneumococcal, and 
hepatitis B vaccines, use aluminum salts. According to the FDA, aluminum 
adjuvant have been associated with rare, severe local reactions, but are 
otherwise safe.53 The FDA states that a child’s lifetime exposure to vaccine-
related aluminum is minimal, and that the risk of aluminum exposure outweighs 
the risk of potential adverse effects. However, the literature examining the effects 
of aluminum adjuvants on infant and child development remains mixed,54–57 and 
should be further investigated.  
Some hesitant individuals worry vaccinations cause the disease they are 
meant to prevent. While it is theoretically possible for a live, attenuated vaccine 
to revert back to its original pathogenic form, this is very rare and has only 
occurred with OPV.15 Furthermore, vaccines that do not replicate in the recipients 




 People are also concerned about serious adverse events (SAEs) to 
vaccines. Mild reactions to vaccines, such as pain, swelling, and redness at the 
injection site, are common and non-life threatening. In contrast, SAEs are life-
threatening and may result in death. Individuals with medical contraindications 
are at higher risk of developing an SAE. The CDC has established guidelines for 
providers on screening patients for contraindications and precautions before 
administering a vaccine.58 Table 4 summarizes contraindications to common 
vaccines. However, according to the CDC’s Vaccine Adverse Event Reporting 
System (VAERS), a national vaccine safety passive surveillance system where 
healthcare providers, vaccine manufactures, and the general public can 
document adverse events post vaccination, SAEs are infrequent and deaths 
related to vaccines are exceedingly rare (Table 5).59,60  
Yet, SAE stories reported on news and social media-outlets often 
sensationalize and overplay the risks of SAEs in order to increase ratings and 
viewership.40 In addition, safety concerns are developed from information 
received through friends and family members. Multiple sources of information 
can conflict and overwhelm an individual, making well-informed medical 
decisions difficult for themselves and their children. Because of modern 
technology, many of these stories and opinions, even when later proven false, 
continue to circulate long after originally created.22,42,45 The now retracted 





Table 4. Contraindications in Common Vaccines.15 
  
Vaccine Contraindications 
DTaP • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a 
vaccine component 
• Encephalopathy (e.g., coma, decreased level of consciousness, prolonged 
seizures), not attributable to another identifiable cause, within 7 days of 
administration of previous dose of DTP or DTaP 
Hepatitis B • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a 
vaccine component 
• Hypersensitivity to yeast 
HPV • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a 
vaccine component, including yeast 
IPV • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a 
vaccine component 
MMR • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a 
vaccine component 
• Pregnancy 
• Known severe immunodeficiency (e.g., from hematologic and solid tumors, 
receipt of chemotherapy, congenital immunodeficiency, long-term 
immunosuppressive therapy or patients with HIV infection who are severely 
immunocompromised) 
• Family history of altered immunocompetence 
Varicella • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a 
vaccine component 
• Known severe immunodeficiency (e.g., from hematologic and solid tumors, 
receipt of chemotherapy, congenital immunodeficiency, long-term 
immunosuppressive therapy or patients with HIV infection who are severely 
immunocompromised) 
• Pregnancy 





Table 5. Expected rates of adverse events following immunization of common child 
vaccines.60 
Vaccine Estimated Rate of Severe Reactions 
BCG (tuberculosis) 1 in 1,000 to 1 in 50,000 doses 
OPV 1 in 2-3 million doses 
Measles 1 in 1 million doses 




In 1998, The Lancet published an article titled “Ileal-lymphoid-nodular 
hyperplasia, non-specific colitis, and pervasive developmental disorder in 
children”.61 Its contents, authored primarily by Andrew Wakefield, suggested 
evidence for a link between the MMR vaccine and development of autism and 
bowel disorders in children. Wakefield was sharply rebuked for his flawed and 
unethical research methods; the study had an exceptionally small sample size 
(n=12) and no control subjects, and Wakefield failed to disclose he had received 
funding from anti-vaccine lobbyists.62 In addition, a journalist named Brian Deer 
uncovered Wakefield had manipulated and falsified data.63 Numerous 
publications following Wakefield et al. have failed to find a casual association 
between the MMR vaccine and autism.64–67 In 2010, the The Lancet fully 
retracted the Wakefield et al. paper, and Wakefield lost his license to practice 
medicine in the United Kingdom.  
 Yet, the debunked paper reinvigorated anti-vaccine sentiment and fueled 
hesitancy of the MMR vaccine throughout the world. A 2005 survey conducted in 
the United Kingdom found a substantial percentage of parents (34%) believed 
there was not enough scientific evidence to disprove a link between the MMR 
vaccine and autism.68 Other publications found similar attitudes and perceived 
safety concerns among North American and European parents.65,69,70 Fallout 
from the Wakefield et al. paper was devastating and widespread. First-dose 
MMR vaccination coverage in London and England sharply decreased in 2003.71 
In parts of Northern Ireland during 2000, the vaccination coverage for measles 
	
25 
fell as low as 60%. In the United States, low second dose MMR coverage during 
the early 2000s was responsible for a mumps resurgence among college 
students in 2006 (Figure 4).72 In France, there were over 20,000 cases of 
measles reported from 2008 to 2011.73  
 The Wakefield et al. paper’s extensive influence largely stemmed from its 
dissemination and perpetuation across mass media.74 The internet and social 
media has drastically changed how people receive their information about 
vaccines. While this can be informative and educational, it has also allowed 
misinformation and non-evidence-based claims to circulate with little-to-no 
oversight. One study showed that a simple Google search with the term 
“vaccination” returns many anti-vaccine websites with false and misleading 
claims.75 This information can influence parents’ perceived safety concerns 
toward specific vaccines or vaccination in general. A study in Canada found 
parents who searched the Internet for vaccination information had 1.6 times the 
odds (95% CI 1.3-2.1) of perceiving vaccines as less safe rather than more safe 
compared to parents who did not search the internet, adjusting for income level, 
internet reliability, age of parent, and region.76 Access to vaccine information has 








Religion, Culture, Awareness, and Personal Beliefs  
 Hesitant individuals commonly cite religious and cultural beliefs as 
reasons to avoid vaccination. As religion and culture are deep-rooted values, it is 
generally harder to dissuade hesitant individuals with religious and cultural 
reasons compared to other hesitant people.22,40 While many religions accept 
vaccination, some may refuse specific vaccines that are counter to the religion’s 
doctrines. For example, there is well documented hesitancy of the human 
papillomavirus (a sexually transmitted infection, HPV) vaccine among parents 
Figure 4. Mumps resurgence, 1993 – 2008.71 First dose MMR coverage 
(dashed line with ‘X’ markers) among 19 to 35-month-olds measured by 
National Immunization Survey (NIS). Second dose MMR coverage (dashed line 
with solid square markers) among 13 to 15-year-olds measured by National 
Health Interview Survey (NHIS). Second dose MMR coverage (dashed line with 
hollow square markers) among 13 to 17-year-olds measured by NIS.  
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with religious views that prohibit premarital sex and/or promote abstinence.77,78 In 
addition, VHPs with religious motives are more likely to outright refuse vaccines 
and vaccination services compared to other VHPs with non-religious reasons.45 
 In the United States, exemptions for vaccinations among kindergarteners 
steadily rose in the 2000s.79 In 2019, six states did not allow for religious 
exemptions for vaccinations.80 In New York and New Jersey, two states where 
religious exemptions are permitted, clusters of measles cases among 
unvaccinated Orthodox Jewish communities were reported to the CDC in 2019.81 
In Europe, a 2013 survey asking 18-40 year-old Dutch Orthodox Protestants their 
intention to vaccinate their current or future children showed about half of 
participants intended to vaccinate their children (55.3%).82 Outbreaks of measles 
in 2009 to 2010 in Zimbabwe were linked to followers of the Apostolic Church of 
Zimbabwe, a religious sect known for refusing most medical interventions, 
including immunization.83 In Muslim majority countries, misconceptions among 
parents believing vaccines contain non-halal ingredients (i.e. pig DNA) has driven 
VH and contributed to outbreaks of polio in Pakistan and measles in Malaysia.84  
The WHO and United Nations Children’s Fund (UNICEF) published results 
from a 2014 survey administered to national immunization managers from 194 
member states. The main objective of the survey was to understand the factors 
that contribute to VH globally. The top three factors reported among all 
participating member states were as follows: 1) risk/benefit (epidemiological and 
scientific evidence), 2) knowledge/awareness, and 3) 
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religion/culture/gender/socio-economic (Figure 5).85 When stratified by WHO 
region, knowledge/awareness was the top reported factor in the African Region, 
while religion/culture/gender/socio-economic was the top reported factor in the 
Region of the Americas (Figure 6).85 In addition, survey results showed that 
higher income countries more frequently cited risk/benefit reasons, such as 
vaccine safety concerns and fear of SAEs, whereas lower income countries more 
frequently cited knowledge/awareness reasons. Similar results were reported 
when the survey was administered again in 2015 to 2017.86 These results 
suggest increasing awareness and knowledge among low income countries may 
help reduce VH. However, there is evidence that education as a determinant of 
VH is correlated with both increases and decreases in vaccination 
acceptance.34,40,72  This is in contrast to education as a determinant of health, 














Figure 6. Top three reasons for vaccine hesitancy 
stratified by WHO region, 2014.84 
Figure 5. Global reasons for vaccine hesitancy, 2014.84 Reasons are grouped by three 
influences for VH: vaccine and vaccination specific issues, individual and group influences, and 
contextual influences.  
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 Personal and philosophical beliefs also drive VH. Unlike religious reasons 
in the United States, only a handful of states allow for personal and philosophical 
based exemptions.80 Yet, these exemptions have major consequences for public 
health and contribute to the reemergence of previously eliminated VPDs.  
 Personal and philosophical reasons for delaying or refusing vaccines are 
diverse. Some VHPs believe natural immunity to VPDs is superior and preferred 
over immunity acquired through vaccination.40,68 Some believe natural infection 
strengthens their child’s immune system and, therefore, is advantageous. Others 
weigh the risk/benefit of vaccinating their child. Vaccines have drastically 
reduced the prevalence of VPDs, leading parents to perceive little-to-no risk of 
their child contracting a VPD and, therefore, believe vaccination is 
unnecessary.68 Others still may understand the risks but view VPDs as non-
serious for their child or think the VPD is easily treatable. Lastly, some parents 
believe healthy diets and life styles can protect from disease.40 
 Instead of outright refusing all vaccines, some parents choose an 
alternative vaccination schedule for their children. In the United States, 
alternative vaccination schedules are on the rise.42,44,46 Parents prefer alternative 
schedules for several reasons; alternative schedules offer delay of some 
vaccines, selective refusal of others, and spacing between a child’s 
recommended vaccines and booster doses. Parents often choose an alternative 
schedule as they are concerned with the number of vaccines their child receives 
during infancy and early childhood. The CDC recommends children be 
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vaccinated for over 10 VPDs by 18 years of age, with the majority of vaccinations 
occurring within the first 15 months after birth (Appendix 2).15 Mohanty et al. 
found parents frequently request pediatricians for alternative vaccination 
schedules.88 Among 374 pediatricians participating in the study, 24% said they 
felt comfortable accommodating parents’ requests.88 Parental interest in 
alternative vaccination schedules gained traction after Dr. Stephanie Cave in 
2001 and Dr. Robert Sears in 2007 published books in support of alternative 
schedules. However, this practice provides no clinical benefit41 Furthermore, 
alternative vaccination schedules can lead to diminished herd immunity, 
significantly increasing the risk of new VPD cases.41 Requests for alternative 
vaccination schedules put clinicians into uncomfortable situations and can strain 
the patient-provider relationship.  
 
The Patient-Provider Relationship 
 Pediatricians and other providers are important determinants of VH. 
Clinicians play a critical role in providing information about vaccines to parents.44 
However, in recent years, parents have shown less confidence in their provider’s 
guidance on vaccines.89,90 The relationship between parent and provider has also 
changed. Today’s access to medical information has resulted in parents having 
more of an active role in their child’s medical decision-making. Although this is 
usually beneficial, parental decisions may be based on inaccurate information 
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and differ from their provider’s recommendations, potentially causing the parent 
to distrust their provider and delay vaccination.40  
Trust in the clinical relationship is vital to parents making well-informed 
decisions about vaccines for their children. Parents use providers to ask 
questions, help navigate claims found on the internet, and seek additional 
information on the safety and efficacy of vaccines.40  However, some providers 
are reluctant and/or unsure how to engage with parents who request additional 
information.40,44,45 This missed opportunity can adversely impact the clinical 
relationship. A study conducted by Gust et al. found that one third of American 
parents felt their clinician did not provide sufficient vaccine information, resulting 
in parents feeling less confident in their provider and less confident in their own 
ability to make well-informed decisions for their children.91  
 Some providers may simply choose to dismiss hesitant individuals and 
their families from their practices. Dismissal policies are highly controversial but 
are increasing in frequency; Hough-Telford et al. reports dismissal policies 
among American pediatricians have increased from 6.1% in 2006 to 11.7% in 
2013 (P=.004).92 In 2016, the American Academy of Pediatrics, an authoritative 
voice on pediatric healthcare standards, condoned dismissal policies as a “last 
resort” option.93 Families who are dismissed may find another provider who 
allows for VH or opt not to receive care.94,95   
Social and cultural factors also influence the clinical relationship. A study 
interviewing immunization managers from several countries was conducted to 
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better understand how providers and health systems affect VH.45 One country 
noted that patients mistreated by healthcare systems felt discouraged from 
returning. Another said providers who held prejudice against certain religious 
groups caused parents to avoid bringing their children to the clinic for future care. 
Gender norms also influence vaccine uptake. In one country where female 
providers are scarce, women forgo vaccines as they prefer to receive vaccination 
services from female providers.45 In another country, women avoid vaccination 





SOLUTIONS TO VACCINE HESITANCY 
 
Motivational Interviewing, Providers and Technology 
 Motivational interviewing (MI) is a patient-centered therapy approach 
designed by psychologists William R. Miller and Stephen Rollnick.96 Originally 
created to treat substance addiction, MI has been adapted for public health and 
medical applications. MI is “a collaborative conversation style for strengthening a 
person’s own motivations and commitment to change”.87 MI allows patients to 
confront their ambivalence about change and make behavioral decisions based 
on their own values and beliefs in a nonjudgmental space with a trained 
professional. This is done through one-on-one or group sessions centered 
around communication skills such as, asking open questions, reflective listening, 
and informing and advising.96 
 MI, when applied within the context of vaccines, is helping increase 
vaccination coverage and reduce VH.79,97,98 In Canada, Gagnuer et al. developed 
a strategy to help educate new parents about vaccination through MI. The 
strategy, named PromoVac, involves a 15-20 minute conversation between 
parents and MI-trained nurses, conducted during the parents’ postpartum 
hospital stay.97 During sessions, parents engage in open conversation and are 
encouraged to raise any questions or doubts they may have. Instead of simply 
providing facts about vaccines, nurses are trained to cover five points of 
conversation: 1) VPDs prevented by the first vaccine series, 2) vaccines and their 
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efficacy, 3) importance of the vaccination schedule, 4) concerns and fears about 
vaccination, and 5) organization of vaccination services.97 In a quasi-
experimental study examining the difference in vaccination coverage among 
infants whose parents received the PromoVac MI interview (treatment group) 
compared to those that did not (control group), a significant increase in 
vaccination coverage of 3.2%, 4.9%, and 7.3% was observed among infants 3, 5, 
and 7 months of age (P < 0.05), respectively.99  
 MI is an effective approach to establishing trust between parent and 
provider. Evidence shows parents are more likely to comply with vaccination 
schedules when they trust their provider.90,98 One qualitative study found that a 
mother’s medical-decision making for her child is influenced by the perceived 
trust between her and her provider, and is more likely to trust the provider when 
she feels her questions have been adequately answered and does not feel 
alienated.100 Providers can also gain parental trust and highlight the importance 
of vaccination by sharing anecdotal stories. Horne et al. highlights that parents 
who received pictures and stories of children suffering from measles during 
vaccination discussions with their provider were more likely to accept vaccines 
compared to parents who only received standard information about vaccination 
services.39   
 In the United States, another strategy known as the “presumptive 
approach” is used to help providers start a conversation with parents about the 
importance and effectiveness of vaccination.101,102 The presumptive approach 
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uses language that assumes the parents already plan on vaccinating their child ( 
e.g. “We’ll do three shots for your son/daughter today”). Participatory language, 
in contrast, can give the impression that vaccination is not necessary (e.g “What 
do you want to do about shots?”). In a 2013 cross-sectional study that 
videotaped 111 parent-provider discussions about vaccinations for their children, 
Opel et al. found parents had a significantly higher odds (adjusted OR = 17.5; 
95% CI = 1.2 – 253.5) of resisting vaccination recommendations if the provider 
used participatory language instead of presumptive language.102 In another 
randomized control trial (RCT) examining parental acceptance of HPV 
vaccination, presumptive language corresponded to higher parental acceptance 
of their child receiving an HPV vaccine compared to the control group.101 More 
recent research conducted by Brewer et al. highlights a 5% increase (95% CI = 
1.1% -9.7%) in HPV coverage among clinics that used the presumptive approach 
compared to control clinics.103 
 Providers also play a vital role is stopping the spread of misinformation. 
However, clinicians’ responses to vaccine misinformation can actually lead to 
increased hesitancy among parents if the response is not performed tactfully.98 
By routinely addressing vaccine myths in the clinic, providers may reinforce 
misinformation. Furthermore, campaigns designed to correct myths about 
vaccines may not be the best approach to increase vaccination coverage. For 
example, Nyhan et al. showed that an intervention using corrective information 
from the CDC about influenza safety led to increased hesitancy in parents with 
	
37 
already high levels of vaccine safety concerns.104 Lewandowsky et al. details 
several strategies providers should employ when confronting cognitive problems 
related to vaccine misinformation (Figure 7). These strategies include sticking to 
clear and simple facts, providing patients with an explicit warning before 
discussing any vaccine myths, and contextualizing the patient’s worldview and 
values. 
However, time constraints and limited resources can make having vaccine 
discussions difficult during office visits.22,105 Furthermore, as previously noted, 
providers must also contend with vaccine myths and misinformation parents 
learn from internet searches and other media.40 Therefore, interventions that 
address VH before hesitant individuals meet with their provider are desirable. 
One RCT examined the effect of a web-based, social media campaigns on early 
childhood vaccination coverage.106 888 mothers were recruited during pregnancy 
and randomly assigned to one of three treatment arms: 1) a website with vaccine 
information and interactive social media components, 2) a website with vaccine 
information only, or 3) standard care only (control). The percentages of infants 
with up-to-date vaccinations by 200 days after birth were 92.5% in the vaccine 
information website and interactive social media group, 91.3% in the vaccine 
information website group, and 86.6% in the control group. In addition, infants in 
the website and social media group had 1.92 times the odds (95% CI 1.07 – 
3.47) of having up-to-date vaccinations by day 200 compared to infants who 
were in the control group.106 Text-message-based interventions have also shown 
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promise.107 Finally, robust monitoring of public sentiments about vaccines across 
various media-outlets can help identify and address VH. The Vaccine Sentimeter 
is an open access data monitoring system, designed to provide real-time 
surveillance of vaccine-related information found on social-media and Internet 
platforms.108 This tool has proven effective at monitoring online trends, enabling 
public health officials to quickly identify and respond to shifts in attitudes about 





Figure 7. Solutions to countering cognitive problems associated with vaccine 
misinformation. Cognitive problems associated with vaccine misinformation are summarized in 






 Policymakers have focused on reducing VH by making vaccination 
mandatory, eliminating nonmedical exemptions, and/or making exemptions more 
difficult to secure. While there is evidence that reducing exemptions corresponds 
to higher coverage rates, elimination of all nonmedical exemptions may not be 
feasible due to political and ethical reasons.110 Furthermore, some legal experts 
argue that making vaccines fully mandatory infringes on personal liberty and the 
freedom to choose.110 Others argue high vaccination coverage is achievable 
through means other than compulsory vaccination. For example, some experts 
suggest incentives and sanctions for healthcare workers may be a more effective 
strategy to increase influenza vaccination coverage than mandatory vaccination 
laws.111 
 Policy at the patient level is also a strategy to combat VH. As previously 
discussed, providers and healthcare systems have adopted policies related to 
the dismissal of individuals and families refusing vaccination. In 2012, a United 
States survey found 21% of pediatricians and 4% of family physicians responded 
“always/often” to dismissing families that refused one or more vaccines.95 
However, experts argue dismissal policies have ethical, legal and public health 
implications, and may cause more harm than good.112,113 A review of Canadian 
vaccine dismissal policies, conducted by  MacDonald et al., contends dismissal is 
an unethical response as it unfairly punishes a child for a decision that is often 
made by their legal guardian.113 Furthermore, dismissal prevents any further 
	
41 
opportunity to work with the family and promote vaccine advocacy. Families who 
are dismissed may also have trouble finding other providers in geographically 
remote regions. Moreover, dismissal policies also weaken solidarity among 
pediatricians and other pediatric providers.112 In some cases, providers who 
dismiss patients may breach their legal obligation to meet the accepted standard 
of care and face legal consequences. Instead, MacDonald et al. suggest 
providers retain vaccine hesitant patients in their practices and work on 
education and building trusted relationships with hesitant families. 
 
Social Norms and Community-based Interventions  
  Adjusting social norms about vaccines can also help reduce VH. Past 
public health campaigns have had success by targeting and changing social 
norms. For example in the United States, changes in public perception around 
smoking in the 1990s has resulted in higher smoking cessation rates among 
young adults today.114 There is evidence that changing social norms at the 
community-level is an effective strategy for combating VH, especially in 
developing countries where lack of awareness/knowledge of vaccines is a strong 
driver of VH. In an RCT, community members from Pakistan’s Lasbela district 
were randomly assigned to one of three discussion-based intervention groups or 
a control group.115 Participants were selected into the study by having 
participated in a prior baseline survey about measles and DTaP vaccinations 
within Lasbela communities. The first intervention group discussed the results 
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from the baseline survey, the second intervention group discussed the costs and 
benefits of childhood vaccination, and the third intervention group discussed local 
action plans to increase coverage. Participants in the three intervention groups 
were encouraged to share their groups’ dialogue with their households and 
communities. In addition, intervention and control groups received a district-wide 
health promotion program emphasizing household hygiene. After adjusting for 
differences between the intervention and control groups, communities who 
received the intervention had a higher odds of vaccinating against measles (OR 
= 2.20; 95% CI = 1.24 – 3.88) and DTaP (OR = 3.36; 95% CI = 2.03 – 5.56).115 In 
another study, dialogue-based community interventions among Nigerian mothers 
were shown to modestly increase the uptake of childhood third-dose DTaP 
vaccination.116 Lastly, a study in India found door-to-door discussions about the 
importance of vaccines between hesitant families and medical personnel led to 
an improved perception of vaccination in general and an increase in polio 
coverage rates.117  
 In the United States, community interventions for VH have also been 
successful. In Washington state during the 2010s, a 3-year community-led 
program called “Immunity Community” was implemented to address rising VH 
sentiment. Immunity Community empowered parents to become vaccination 
advocates and start dialogue about the importance of vaccines with others in 
their community. Parents interested in the program were provided 
comprehensive training on how to best approach and engage in vaccine-related 
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community-based discussions. Pre- and post-intervention survey results showed 
the program successfully decreased VH and improved vaccine-related attitudes 
among parents in the intervention communities.118 Over the 3-year period, 
parental concern about other parents not vaccinating their children rose from 
81.2% to 88.6% (P < 0.05), while parents self-identifying as “vaccine hesitant” fell 
from 22.6% to 14.0% (P < 0.05).  
Community-based interventions offer several advantages over other 
solutions. A key component of community-based interventions is collaboration 
with trusted community leaders and figures who promote vaccination. This type 
of intervention is well positioned to address distrust of vaccines among 
communities, one of hardest determinants of VH to manage. Public health 
partnerships with religious leaders and groups have also shown to increase 
vaccination coverage among congregations.119 A systematic review of literature 
related to VH interventions found community-based interventions are most 
successful when they directly target unvaccinated or under-vaccinated 
populations.120 Finally, grassroot interventions are especially important in 
resource-deficient and developing regions where primary care and medical 
infrastructure is scarce. The WHO recommends additional focus on community-
based models, particularly in Africa, in order to achieve global elimination and 






 Vaccines are one of the most successful public health interventions in 
human history. Their development has led to the eradication of smallpox and has 
reduced the global prevalence of several other VPDs. However, VH poses a 
significant threat to this progress, and can lead an individual to selectively avoid 
some vaccines, delay recommended vaccination schedules, or outright refuse 
vaccination services. The consequences of VH are devastating, leading to the 
reemergence of once eliminated VPDs. VH will need to be addressed if global 
disease elimination and eradication goals are to be achieved.  
VH is a complex issue with no single solution. Further research is needed 
to understand and develop the most effective strategies to combat VH. As 
previously outlined, these interventions will require a multifaceted approach and 
should take into account social and region-specific factors. For example, 
interventions that mitigate risk/benefit concerns about vaccines may be most 
effective in developed countries like the United States and the United Kingdom. 
In contrast, community-driven interventions that focus on vaccine 
knowledge/awareness are strong approaches in developing countries. In 
addition, public health officials can assuage vaccine safety fears by changing or 
substituting vaccine ingredients. Although the FDA took this approach when 
pulling thimerosal from vaccines approved in the United States, it may not be 
cost-effective and is counter to evidence-based research and scientific 
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reasoning. Public health officials should also focus on technology and its function 
in disseminating vaccine information, as well as its utility in monitoring public 
trends and sentiments about vaccination. However, focusing on parental 
attitudes about vaccines and understanding their decision-making process is 
paramount. Providers can take steps to correct misinformation and encourage 
hesitant families toward vaccination through effective communication strategies. 
Finally, additional research on policy-based interventions is needed, especially 
policy that leads to compulsory vaccination mandates as this type of legislation 
can cause more harm than benefit.  
 VH presents a public health challenge for containing novel infectious 
diseases. The world is currently grappling with a global pandemic of coronavirus 
disease 2019 (COVID-19). COVID-19 is caused by the severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) and was first discovered in Wuhan, 
China in December 2019. As of July 2020, there were over 4,000,000 total cases 
and 140,000 deaths in the United States,122 and over 15,000,000 total cases and 
600,000 deaths globally.123 Currently, there is no vaccine for COVID-19. As 
researchers around the world race to develop a vaccine, public health experts 
warn resistance to a new vaccine may undermine efforts to end the pandemic. 
Already, misinformation and conspiracy theories about a COVID-19 vaccine are 
spreading throughout the world. An online survey was recently conducted in the 
United Kingdom to understand people’s level of endorsement of coronavirus-
related conspiracy theories. Of 2,051 respondents, 25% reported some level of 
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endorsement, 15% reported a consistent pattern of endorsement, and 10% 
reported very strong endorsement.124 High levels of endorsement of COVID-19-
related conspiracy theories were associated with lower confidence in government 
guidelines and lower willingness to be vaccinated.124 In Pakistan, prominent 
political leaders have raised fictitious theories that the SARS-CoV-2 virus was 
invented by the outside world to attack Muslim countries and have actively 
encouraged citizens to avoid vaccination.125 In the United States, President 
Donald Trump has falsely stated the virus was invented in a Chinese laboratory, 
a racist theory that is widely shared by several American media personalities and 
anti-vaccination groups. While these results and stories are disturbing, they are 
not entirely surprising and reaffirm the effect misinformation has on VH. The 
previously outlined strategies for reducing VH will be crucial to achieving proper 
herd immunity for COVID-19. Providers and public health authorities can start 
addressing VH now by transparently communicating what is known about 
potential vaccine candidates, in addition to stressing the importance of being 
vaccinated. It may also be helpful to compare future COVID-19 vaccination 
campaigns to successful vaccination campaigns of the past, like polio and 
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